Amyotrophic Lateral Sclerosis - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Amyotrophic Lateral Sclerosis

The Experts below are selected from a list of 87336 Experts worldwide ranked by ideXlab platform

Amyotrophic Lateral Sclerosis – Free Register to Access Experts & Abstracts

Michael Swash – One of the best experts on this subject based on the ideXlab platform.

  • Amyotrophic Lateral Sclerosis: an update
    Current Opinion in Neurology, 2011
    Co-Authors: Mamede De Carvalho, Michael Swash

    Abstract:

    Purpose of reviewThe aim is to review recent publications on Amyotrophic Lateral Sclerosis (ALS).Recent findingsThe Awaji recommendations for electrophysiological diagnosis will permit earlier clinical trials entry. The use of ultrasound to visualize fasciculations, even in deep muscles, will contri

  • el escorial revisited revised criteria for the diagnosis of Amyotrophic Lateral Sclerosis
    Amyotrophic Lateral Sclerosis, 2000
    Co-Authors: Benjamin Rix Brooks, Michael Swash, Robert G. Miller, Theodore L. Munsat

    Abstract:

    (2000). El Escorial revisited: Revised criteria for the diagnosis of Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Vol. 1, No. 5, pp. 293-299.

  • Criteria for Diagnosis of Familial Amyotrophic Lateral Sclerosis
    Neuromuscular disorders : NMD, 1992
    Co-Authors: Michael Swash, Nigel Leigh

    Abstract:

    Clinical criteria for the diagnosis of motor neuron disease, agreed at the inaugural meeting of the European Familial Amyotrophic Lateral Sclerosis Collaborative Group, are described. The criteria are derived from those developed for the study of sporadic Amyotrophic Lateral Sclerosis, and allow the inclusion of certain recognized clinical sub-types of familial Amyotrophic Lateral Sclerosis. They will require testing for consistency and sensitivity.

H. Norris – One of the best experts on this subject based on the ideXlab platform.

  • Spinal Fluid Cells and Protein in Amyotrophic Lateral Sclerosis
    Archives of neurology, 1993
    Co-Authors: Forbes H. Norris, W. Burns, E. Mukai, H. Norris

    Abstract:

    • The cerebrospinal fluid total protein in 385 cases of sporadic Amyotrophic Lateral Sclerosis showed no relationship to survival, but it was related to survival time in 34 cases of familial Amyotrophic Lateral Sclerosis. Infrequent and mild pleocytosis, and oligoclonal bands seemed to have no clinical significance in well established cases of Amyotrophic Lateral Sclerosis.

Fang Fang – One of the best experts on this subject based on the ideXlab platform.

  • Lipids, apolipoproteins, and prognosis of Amyotrophic Lateral Sclerosis.
    Neurology, 2020
    Co-Authors: Caroline Ingre, Lin Chen, Yiqiang Zhan, Jet Termorshuizen, Li Yin, Fang Fang

    Abstract:

    Objective To determine whether lipids and apolipoproteins predict prognosis of patients with Amyotrophic Lateral Sclerosis in a cohort study of 99 patients with Amyotrophic Lateral Sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. Methods Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of Amyotrophic Lateral Sclerosis diagnosis or shortly thereafter. Death after Amyotrophic Lateral Sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after Amyotrophic Lateral Sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. Results A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p Conclusions Lipids and apolipoproteins are important prognostic indicators for Amyotrophic Lateral Sclerosis and should be monitored at the diagnosis of Amyotrophic Lateral Sclerosis.

  • Lipids, apolipoproteins, and prognosis of Amyotrophic Lateral Sclerosis
    'Ovid Technologies (Wolters Kluwer Health)', 2020
    Co-Authors: Ingre Caroline, Li Yin, Chen Lin, Zhan Yiqiang, Termorshuizen Jet, Fang Fang

    Abstract:

    Objective: To determine whether lipids and apolipoproteins predict prognosis of patients with amyo- trophic Lateral Sclerosis in a cohort study of 99 patients with Amyotrophic Lateral Sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden.

    Methods: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of Amyotrophic Lateral Sclerosis diagnosis or shortly thereafter. Death after Amyotrophic Lateral Sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after Amyotrophic Lateral Sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate.

    Results: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after Amyotrophic Lateral Sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables.

    Conclusions: Lipids and apolipoproteins are important prognostic indicators for Amyotrophic Lateral Sclerosis and should be monitored at the diagnosis of Amyotrophic Lateral Sclerosis.Swedish Research CouncilEuropean Research CouncilPublishe